电子决策支持系统作为治疗干预在多中心PICU临床试验中的表现:心肺衰竭-儿科胰岛素滴定试验(HALF-PINT)
本研究为观察性回顾性研究,分析HALF-PINT随机对照试验中使用CHECKS电子决策支持系统管理高血糖的依从性。32个中心共698名危重患儿,其中658名接受CHECKS方案治疗≥24小时,每患者建议中位数119条,依从性中位数99.5%,仅30例依从性低(<90%)。低依从性患者来自32个中心中的16个,更年轻(P=0.02),更少使用正性肌力药(P=0.04),更多被随机分配到较低血糖目标(80% vs 48%;P<0.001),处于目标血糖时间更短(53% vs 75%;P<0.001)。CHECKS为危重患儿高血糖管理提供了高度可重复且明确的方法。
要点
- 658/698名危重患儿接受CHECKS方案≥24小时,每患者建议中位数119条,依从性中位数99.5%,仅30例依从性<90%。
- 低依从性患者来自32个中心中的16个,更年轻(P=0.02),更少使用正性肌力药(P=0.04)。
- 低依从性患者更多被随机分配到较低血糖目标(80% vs 48%;P<0.001),处于目标血糖时间更短(53% vs 75%;P<0.001)。
- 超控(overrides)89%归因于用户因素,患者因素占29%。
- CHECKS为危重患儿高血糖管理提供了高度可重复且明确的方法,电子决策支持系统是开展复杂儿科重症临床试验的重要机制。
适用人群与场景
- 危重儿科患者,来自32个中心,参与HALF-PINT试验并接受CHECKS方案治疗≥24小时。
处置流程与药物剂量
- 使用CHECKS电子决策支持工具管理高血糖,具体方案未在本文详述。
研究设计与关键结果
- 观察性回顾性研究,分析HALF-PINT随机对照试验中使用CHECKS的依从性;32个中心,698名患儿中658名接受CHECKS方案≥24小时。
- 每患者建议中位数119条,依从性中位数99.5%,仅30例依从性低(<90%)。
- 低依从性患者来自32个中心中的16个,更年轻(P=0.02),更少使用正性肌力药(P=0.04)。
- 低依从性患者更多被随机分配到较低血糖目标(80% vs 48%;P<0.001),处于目标血糖时间更短(53% vs 75%;P<0.001)。
- 超控89%归因于用户因素,患者因素占29%。
证据类型、等级与局限
- 证据类型:观察性回顾性研究,嵌套于前瞻性随机对照试验(HALF-PINT)。
- 局限:原文未报告局限性。
对床旁实践的改变
- CHECKS电子决策支持系统在危重患儿高血糖管理中具有高依从性(中位数99.5%),但低依从性患者更年轻、更少使用正性肌力药、更多被分配到较低血糖目标且处于目标血糖时间更短。
- 电子决策支持系统可用于在多样环境中实施明确且可重复的复杂儿科重症临床试验方案。
指南或共识出处
- HALF-PINT试验(NCT01565941,注册于2012年3月29日)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The use of electronic clinical decision support (CDS) systems for pediatric critical care trials is rare. We sought to describe in detail the use of a CDS tool (Children's Hospital Euglycemia for Kids Spreadsheet [CHECKS]), for the management of hyperglycemia during the 32 multicenter Heart And Lung Failure-Pediatric Insulin Titration trial.
RESEARCH QUESTION: In critically ill pediatric patients who were treated with CHECKS, how was user compliance associated with outcomes; and what patient and clinician factors might account for the observed differences in CHECKS compliance?
STUDY DESIGN AND METHODS: During an observational retrospective study of compliance with a CDS tool used during a prospective randomized controlled trial, we compared patients with high and low CHECKS compliance. We investigated the association between compliance and blood glucose metrics. We describe CHECKS and use a computer interface analysis framework (the user, function, representation, and task analysis framework) to categorize user interactions. We discuss implications for future randomized controlled trials.
RESULTS: Over a 4.5-year period, 658 of 698 children were treated with the CHECKS protocol for ≥24 hours with a median of 119 recommendations per patient. Compliance per patient was high (median, 99.5%), with only 30 patients having low compliance (<90%). Patients with low compliance were from 16 of 32 sites, younger (P = .02), and less likely to be on inotropic support (P = .04). They were more likely to be have been assigned randomly to the lower blood glucose target (80% vs 48%; P < .001) and to have spent a shorter time (53% vs 75%; P < .001) at the blood glucose target. Overrides (classified by the user, function, representation, and task analysis framework), were largely (89%) due to the user with patient factors contributing 29% of the time.
INTERPRETATION: The use of CHECKS for the Heart And Lung Failure-Pediatric Insulin Titration trial resulted in a highly reproducible and explicit method for the management of hyperglycemia in critically ill children across varied environments. CDS systems represent an important mechanism for conducting explicit complex pediatric critical care trials.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01565941, registered March 29 2012; https://clinicaltrials.gov/ct2/show/NCT01565941?term=HALF-PINT&draw=2&rank=1.
参考来源
- Hirshberg EL, Alexander JL, Asaro LA, et al. Performance of an Electronic Decision Support System as a Therapeutic Intervention During a Multicenter PICU Clinical Trial: Heart and Lung Failure-Pediatric Insulin Titration Trial (HALF-PINT). Chest. 2021. PMID: 33932465. doi:10.1016/j.chest.2021.04.049
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。